Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Asociación de Familiares de Alzheimer de Valladolid | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The goal of this non-randomized clinical trial is to assess the effects of strength training in the physical function of Alzheimer's disease (AD) patients. The main question it aims to answer are:
Participants in the exercise group will perform a 16-weeks program divided in two phases (phase 1: basic strength training; phase 2: AMRAP training). Participants in both (exercise and control) groups will receive their usual care treatments which include occupational therapy, musicotherapy, cognitive stimulation and sensory stimulation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Supervised Physical Activity (Phase I: Strength training; Phase II: AMRAP training) | Experimental | These patients, in addition to receiving the usual treatment for their pathology, carry out supervised activity consisting of:
|
|
| Control | No Intervention | These patients only receive the usual treatment for their pathology. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2 | Other | 20-30 min/session, 3 times/week for 4 weeks. After a 5-min warm-up, participants perform a moderate-intensity functional training program. This program is designed in circuit mode consisting of 6 global functional exercises: i) sit and stand, ii) forward lunges, iii) chest press, iv) high row, v) lateral shoulder raises and vi) heel raises. Participants must complete the highest number of repetitions and/or rounds as possible (AMRAP) in 15-min without a designated rest. |
| Measure | Description | Time Frame |
|---|---|---|
| Short Physical Performance Battery | Changes in the SPPB Score (Short Physical Performance Battery; Range between 0 "worst performance" and 12 "best performance") | 0 weeks, 12 weeks, 16 weeks of intervention. 8 weeks of detraining |
| Measure | Description | Time Frame |
|---|---|---|
| Handgrip strength | Changes in the hang-up strength in the dominant side | 0 weeks, 12 weeks, 16 weeks of intervention. 8 weeks of detraining |
| Body mass index | Changes in the body mass index |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universidad Europea Miguel de Cervantes | Valladolid | 47012 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D003704 | Dementia |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
Not provided
Not provided
Non-randomized controlled trial
Not provided
Not provided
The persons analyzing the data collected (investigators, statician) will not know to which group each person belongs.
|
|
| Supervised Physical Activity: Phase 1 | Other | 40-60 min/session, 3 times/week for 12 weeks. After a 5-min warm-up, participants performed 6 global functional exercises: i) sit-to-stand; ii) chest press, iii) forward lunges; iv) unilateral shoulder raises; v) unilateral row; and vi) heel raises. The initial volume is 2 sets and 8 repetitions and it will progressively increase until 3 sets and 12 repetitions. |
|
|
| 0 weeks, 12 weeks, 16 weeks of intervention. 8 weeks of detraining |
| Practicability of AMRAP (As Many Repetitions As Possible) training; it will be analysed by calculating both intra- and inter-subject coefficient variation. | This variable evaluates the applicability of this tipe of training in patients with Alzheimer disease | Every session (during 13 sessions) |
| D019636 |
| Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D001519 | Behavior |